Hawley’s NUCLEAR Strike on Mifepristone Access

Senator Josh Hawley’s new legislation aims to completely strip FDA approval from the abortion pill mifepristone, marking the most aggressive federal push yet to ban a drug now used in nearly two-thirds of all abortions nationwide.

Story Snapshot

Hawley’s Safeguarding Women from Chemical Abortion Act seeks full FDA approval withdrawal of mifepristone for abortion use
Bill allows women harmed by the drug to sue manufacturers like Danco Laboratories directly
Legislation targets Biden-era deregulation that enabled telehealth and mail-order access without in-person medical oversight
Research cited shows complications 22 times higher than FDA label acknowledges, with mifepristone now accounting for 63% of U.S. abortions

Hawley Takes Aim at Biden’s Abortion Pill Deregulation

Senator Josh Hawley introduced the Safeguarding Women from Chemical Abortion Act on March 10, 2026, escalating his fight against what he calls an “inherently dangerous” drug pushed on women for corporate profit. The Missouri Republican hosted a Washington press conference featuring testimonies from women allegedly harmed by mifepristone and pro-life leaders who detailed the drug’s risks. Unlike his 2025 legislation that focused on restoring safety requirements, this bill demands complete FDA approval revocation for abortion use and classifies distribution for pregnancy termination as a federal crime. Representative Diana Harshbarger, a pharmacist from Tennessee, announced she would introduce companion legislation in the House.

Biden Administration Removed Critical Safety Protections

The FDA originally approved mifepristone in 2000 with strict in-person dispensing requirements to monitor potential complications. Biden administration bureaucrats systematically dismantled these safeguards between 2021 and 2023, allowing telehealth consultations and mail-order distribution without requiring women to see doctors face-to-face. This reckless deregulation coincided with mifepristone’s use skyrocketing to 63 percent of all U.S. abortions by 2023, totaling over one million procedures according to Guttmacher Institute data. Pro-life groups estimate approximately 500 women now receive these pills daily through the mail, with no medical professional present to address emergencies like severe bleeding or incomplete abortions requiring surgical intervention.

Underreported Complications and Corporate Profiteering

Research from the Ethics and Public Policy Center reveals mifepristone complications occur 22 times more frequently in real-world use than the FDA’s official labeling acknowledges. Hawley’s legislation directly confronts this discrepancy by enabling women who suffer harm to file lawsuits against manufacturers like Danco Laboratories, which has generated billions in revenue from the drug. Harshbarger emphasized that real-world evidence demands accountability over political considerations, calling for transparency that prioritizes women’s safety. The bill aligns with ongoing Trump administration reviews of mifepristone safety data, though Hawley insists Congress must act independently rather than waiting for bureaucratic processes that could drag on indefinitely while women continue facing preventable medical emergencies.

Pro-Life Coalition Rallies Behind Hawley’s Legislation

Concerned Women for America Legislative Action Committee praised Hawley’s bill as a necessary confrontation of the abortion pill’s documented dangers, issued the day after introduction. The legislation represents Hawley’s third major pro-life push in recent months, following his October 2025 bill to extend Hyde Amendment restrictions to Obamacare-funded abortions. FDA Commissioner Marty Makary, confirmed under the Trump administration, previously pledged to review mifepristone data and restore safety standards after Hawley’s May 2025 letters requesting action. While the Supreme Court unanimously dismissed a 2024 challenge to mifepristone access on procedural standing grounds without addressing safety merits, this congressional approach bypasses courts entirely. The bill’s fate remains uncertain with no scheduled vote, but it signals conservatives’ determination to reverse Biden-era abortion expansions.